Financials
Financial year 2025
Lansinoh Laboratories Benelux from Herentals, company number BE0630939468, closed financial year 2025 with a result of € 472,688 after tax. For that financial year Lansinoh Laboratories Benelux recorded a gross margin of € 887,520 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 193,701 to € 472,688. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 1.6 million
▼ 32% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 472,688
▲ 144% vs 2024
Profit after tax over the fiscal year.
€ 1.9 million
▲ 105% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.2 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
2.9
▼ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 223,637
▲ 1% vs 2024
€ 77,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,204
▼ 29% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 212,096
▲ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 95,748
▲ 12% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 471,258 | € 415,834 | € 587,137 | € 887,520 | ▲ 51% |
| Profit after taxes | € 132,732 | € 158,756 | € 193,701 | € 472,688 | ▲ 144% |
| Equity | € 1,955,645 | € 2,114,401 | € 2,308,102 | € 1,580,790 | ▼ 32% |
| Total debts | € 851,321 | € 457,418 | € 276,464 | € 1,526,523 | ▲ € 1.3 million |
| Cash | € 461,540 | € 604,312 | € 911,174 | € 1,868,350 | ▲ 105% |
| Retained profit | € 1,893,645 | € 2,052,401 | € 2,246,102 | € 1,518,790 | ▼ 32% |
| Dividend | € 0 | € 0 | € 0 | € 1,200,000 | |
| Balance sheet total | € 2,806,966 | € 2,571,819 | € 2,584,566 | € 3,107,313 | ▲ 20% |
| Employees (FTE) | 2.3 | 2.8 | 3 | 2.9 | ▼ 0.1 |
Key figures of Lansinoh Laboratories Benelux, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Lansinoh Laboratories Benelux?
What happened at Lansinoh Laboratories Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Vanessa Cook stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 472,688 (▲ 144% vs 2024). Source: NBB ↗
- Julie Talbot became a director. NBB
- Kevin Vyse-Peacock stepped down as director. NBB
- Kevin Vyse-Peacock became a director. NBB
- Vanessa Cook became a director. NBB
- New establishment in Herentals. KBO
- Start of the company according to the CBE. KBO
In short
From € 132,732 profit in 2022 to € 472,688 profit in 2025.
Paid € 396,746 in corporate taxes since 2022.
Best year ever: 2025, with € 472,688 profit.
On average € 306,000 of value added per employee in 2025.
A new publication or filing at Lansinoh Laboratories Benelux? We notify you, reason included.
Follow Lansinoh Laboratories BeneluxDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Lansinoh Laboratories Benelux is Julie Talbot. It owns 100% of Lansinoh Laboratories France SAS itself.
Directors
According to the 2025 annual accounts
Julie Talbot
Director
since 2026
Kevin Vyse-Peacock
Director
since 2024 · until 2026
Vanessa Cook
Managing director
since 2024 · until 2031
Establishments
Establishment units
Physical locations of this company
Diamantstraat (HRT) 8 box 383
2200 Herentals
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0630.939.468
- VAT number
- BE 0630.939.468
- Registered office
- Diamantstraat (HRT) 8 bus 383, 2200 Herentals
- Names & denominations
- Lansinoh Laboratories Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 May 2015
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Verhuur en lease van medisch en paramedisch materieel
Reparatie en onderhoud van andere apparatuur
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels